<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895569</url>
  </required_header>
  <id_info>
    <org_study_id>20120021548</org_study_id>
    <nct_id>NCT01895569</nct_id>
  </id_info>
  <brief_title>Triple Therapy in Type 2 Diabetic Patients</brief_title>
  <official_title>Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of type 2 diabetes mellitus often requires the use of one or more hypoglycemic
      agents to reach the adequate glycemic control. The aim of the study is to evaluate the
      effects of a triple therapy with metformin, pioglitazone and sitagliptin on glycemic
      variability compared to metformin monotherapy, and compared to a combination of metformin and
      pioglitazone. To assess glycemic variability a continuous glucose monitoring system will be
      used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an estimated temporal space of about 3 years, 64 not well controlled, type 2 diabetic
      patients will be recruited.

      Patients will be instructed to take metformin 500 mg three times a day for the first three
      months, then pioglitazone 15 mg twice a day will be added for further three months, and
      finally sitagliptin 100 mg once a day will be added for the last three months. At the
      baseline, and every three months a continuous glucose monitoring system will be performed.

      At any stage of the study, if the value of glycated hemoglobin reach the desired goal
      (&lt;6.5%), participation in the study will be stopped and the patient will not be subjected to
      further adjustments of hypoglycemic therapy or additional continuous monitoring glucose.

      After collection of written informed consent, the following data will be collected:

        -  History: type of diabetes, comorbidities, current medication, duration of diabetes and
           complications, voluptuary habits such as tobacco smoke (both number of packets/year and
           n° packets/day), alcohol consumption, coffee consumption, physical activity.

        -  Physical exam, general anthropometric parameters such as weight, height, circumference,
           body mass index, waist-hip ratio, and blood pressure.

        -  Assessment of glycemic variability every three months using a continuous glucose
           monitoring system.

        -  Collection of blood and urine samples to assess: glycated hemoglobin, fasting plasma
           glucose (FPG), post-prandial glucose (PPG), fasting plasma insulin (FPI), HOMA-index
           (HOMA-IR and HOMA-β), high sensitivity C-reactive protein (hs-CRP), total cholesterol,
           LDL-cholesterol, HDL-cholesterol, tryglicerides, lipoprotein (a) [Lp(a)],
           metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion molecules
           (sICAM-1, sVCAM-1), sE-selectin, adiponectin (ADN), complete urinalysis, 24-hour
           microalbuminuria.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>9 months</time_frame>
    <description>Glycemic variability will be assessed at the baseline, and every three months, using a continuous glucose monitoring system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glyco-metabolic control</measure>
    <time_frame>9 months</time_frame>
    <description>Glyco-metabolic control will be assessed evaluating glycated hemoglobin, fasting plasma glucose and post-prandial glucose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin-resistance parameters</measure>
    <time_frame>9 months</time_frame>
    <description>Insulin-resistance parameters will be assessed using HOMA-index (HOMA-IR and HOMA-β).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin &gt; 6.5%, and &lt; 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin will be added to therapy for the first threre months.</description>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <other_name>500 mg three times a day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>In patients not well controlled (glycated hemoglobin &gt;6.5%) after three months of metformin, pioglitazone will be added.</description>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <other_name>15 mg twice a day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>In patients not well controlled (glycated hemoglobin &gt;6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.</description>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <other_name>100 mg once a day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetic patients

          -  naive to therapy

          -  glycated hemoglobin &gt; 6.5 and &lt; 9.0 %

        Exclusion Criteria:

          -  hepatic and renal diseases

          -  recent cardiovascular diseases

          -  previous pancreatitis

          -  history of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Derosa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Matteo Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Derosa, MD, PhD</last_name>
    <email>giuseppe.derosa@unipv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Maffioli, MD</last_name>
    <email>pamelamaffioli@hotmail.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo Foundation</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD, PhD</last_name>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Maffioli, MD</last_name>
      <email>pamelamaffioli@hotmail.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Derosa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pamela Maffioli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

